Civardi, G.; Medioli, A.; Braghieri, C.; Ambroggi, M.; Immovilli, P.; Orsucci, S.; Contini, P.; Aronica, G.; Cavanna, L. Autoimmune Encephalitis following Checkpoint Inhibitor Therapy in a Patient with Metastatic Melanoma in Complete Remission. Medicina2024, 60, 728.
Civardi, G.; Medioli, A.; Braghieri, C.; Ambroggi, M.; Immovilli, P.; Orsucci, S.; Contini, P.; Aronica, G.; Cavanna, L. Autoimmune Encephalitis following Checkpoint Inhibitor Therapy in a Patient with Metastatic Melanoma in Complete Remission. Medicina 2024, 60, 728.
Civardi, G.; Medioli, A.; Braghieri, C.; Ambroggi, M.; Immovilli, P.; Orsucci, S.; Contini, P.; Aronica, G.; Cavanna, L. Autoimmune Encephalitis following Checkpoint Inhibitor Therapy in a Patient with Metastatic Melanoma in Complete Remission. Medicina2024, 60, 728.
Civardi, G.; Medioli, A.; Braghieri, C.; Ambroggi, M.; Immovilli, P.; Orsucci, S.; Contini, P.; Aronica, G.; Cavanna, L. Autoimmune Encephalitis following Checkpoint Inhibitor Therapy in a Patient with Metastatic Melanoma in Complete Remission. Medicina 2024, 60, 728.
Abstract
A 68-year-old man with malignant metastatic melanoma in complete remission after Pembrolizumab treatment, developed 10 months after Pembrolizumab cessation due a grade 3 diarrhea, confusion, altered mental status, progressive memory loss, gait disturbance. He was admitted to the neurologic department and comprehensive neurological workup, brain magnetic resonance imaging, cerebral fluid analysis, EEG, blood test allowed the diagnosis of autoimmune encephalitis. The patient was treated with plasmapheresis, high dose of intravenous steroids and intravenous immunoglobulins. The patient improved and he is now well with a performance status 1. This case is interesting since the AE developed approximately 10 months after the cessation of immunotherapy, the underlying cancer was in complete remission and the AE showed a good response to the treatment done.
Medicine and Pharmacology, Oncology and Oncogenics
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
